Login to Your Account

Atugen Raises EUR5M As Fuel For SiRNA Drug Development

By Douglas Merrill

Wednesday, March 24, 2004
Following a change in strategy made public last month, Atugen AG secured €5 million in the first closing of its third round of financing. The company intends to use the new capital to accelerate its work on small interfering RNA therapeutics. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription